Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Immune · Investigational

VIP (Vasoactive Intestinal Peptide)

No lawful US pathway

Tell me if this changesRead the free 2026 Peptide Safety Checklist →
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and immune cells. VIP acts through VPAC1 and VPAC2 receptors and is an endogenous anti-inflammatory neuropeptide that shifts the balance away from pro-inflammatory factors and induces regulatory T cells (PMID 17934101).

It also functions as a vasodilator, bronchodilator, and neuromodulator. A synthetic form is known as aviptadil.

02 · Research summary & key findings

In an open phase 2 study of 20 patients with active sarcoidosis, inhaled VIP was well tolerated, reduced TNF-alpha production by lung lavage cells, and increased regulatory T cells (PMID 20442436). In 20 patients with pulmonary hypertension, a single inhaled dose produced modest, short-lived selective pulmonary vasodilation (PMID 18978135). In the TESICO randomized trial in COVID-19 respiratory failure, intravenous aviptadil did not improve 90-day outcomes compared with placebo (PMID 37348524). Claims of benefit in mold-associated chronic inflammatory response syndrome (CIRS) are not supported by controlled trials indexed in PubMed.

03 · Regulatory status

VIP (Vasoactive Intestinal Peptide) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

No lawful pathway today

VIP (Vasoactive Intestinal Peptide) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.

See the 1 FDA-approved compound in Immune

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

04 · Administration routes

  • Intranasal
  • Intravenous
  • Subcutaneous injection

References

  1. [1]Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy Ann Rheum Dis, 2007. PMID 17934101
  2. [2]Inhalation of vasoactive intestinal peptide in pulmonary hypertension Eur Respir J, 2008. PMID 18978135
  3. [3]Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis Am J Respir Crit Care Med, 2010. PMID 20442436
  4. [4]Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial Lancet Respir Med, 2023. PMID 37348524

Primary literature

  • PubMed: "VIP"

    Peer-reviewed literature indexed by the National Library of Medicine.

  • ClinicalTrials.gov: "VIP"

    Registered interventional and observational studies, including status and phase.

  • PubChem: "VIP"

    Chemical structure, molecular properties, and bioactivity data.

Related peptides in Immune

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.